Plain-English translation of NCT07101432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new type of immunotherapy using TROP2 CAR/IL-15 TGFBR2 KO NK cells—immune cells that are grown in a laboratory, trained to recognize and attack cancer cells, and infused into your body. Some participants will also receive a targeted form of radiation therapy before the cell infusion to help prepare your body. The goal is to learn whether this treatment is safe and whether it can help shrink or control your cancer.
Advanced head and neck cancers that return after standard treatments like chemotherapy or radiation are very difficult to treat, and patients often have limited options. Researchers are exploring whether this new type of engineered immune cell therapy, possibly combined with radiation, could offer a new way to help patients whose cancers have stopped responding to conventional treatments.
You likely qualify if…
You likely don't qualify if…
You will receive treatment on an outpatient basis, meaning you will not need to stay overnight at the hospital. First, you will receive lymphodepleting chemotherapy (a brief course of chemotherapy designed to prepare your body for the new cells). Depending on which arm of the study you are assigned to, you may also receive targeted radiation therapy to one or more tumors before receiving the infused engineered immune cells. After the cell infusion, you will have regular follow-up visits to monitor for side effects, check how your cancer is responding, and perform blood tests to track the cells in your body.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States